Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solbinsiran Phase 1 in Dyslipidemia
NCT04644809Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- May 2022
- Modality
- Antisense DNA, Conjugated siRNA, MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of solbinsiran in dyslipidemia (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration. Started Nov 2020; status: completed.
02
Drugs
solbinsiran
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04644809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04644809.